Background

Eumycetoma, also known as fungal mycetoma or maduromycosis,

is a chronic infectious disease that affects the skin, subcutaneous tissues, and sometimes bones. It is one of the two main types of mycetoma, the other being actinomycetoma, caused by bacteria. Eumycetoma is explicitly caused by certain fungi and is characterized by the formation of granules or grains within the affected tissues.

The primary causative agents of eumycetoma are fungi belonging to various genera, including Madurella, Scedosporium, Pseudallescheria, and Fusarium, among others. These fungi are typically found in soil, decaying vegetation, or organic matter. Infection occurs when fungal spores enter the body through a wound, a cut, or even a small puncture, commonly on the foot. Once inside, the fungi begin to grow and increase, leading to the development of mycetoma.

Eumycetoma typically presents as a painless, slowly progressive swelling or mass in the affected body part, most commonly the foot. The infection can spread to the surrounding tissues, leading to the formation of abscesses and draining sinuses. Over time, the fungi can invade the bones, causing bone destruction and deformities.

Epidemiology

• Geographic Distribution: Eumycetoma is endemic in several countries, predominantly in Africa, the Indian subcontinent, and parts of Central and South America. Specific countries with high prevalence include Sudan, India, Mexico, and Venezuela.
• Age and Gender: Eumycetoma can affect individuals of all ages, but it is more commonly reported in adults, particularly those engaged in agricultural or outdoor activities. There is no significant gender predilection; males and females can be affected.
• Occupational Risk: Occupational risk factors play a crucial role in eumycetoma transmission. Agricultural workers, farmers, and individuals involved in activities that expose them to soil and thorny plants are at a higher risk of acquiring the infection.
• Socioeconomic Impact: Eumycetoma is considered a neglected tropical disease, and its impact is more profound in low-income communities with limited access to healthcare resources. The disease’s chronic nature and associated disabilities can lead to considerable social and economic burdens on affected individuals and their families.

Anatomy

Pathophysiology

The pathogenesis of eumycetoma is not fully understood, but it involves several key steps:

• Entry and Establishment: The infection begins when fungal spores enter the body through a break in the skin, such as a wound, cut, or puncture. The spores establish themselves in the subcutaneous tissues, where they find a suitable environment to grow and thrive.
• Fungal Growth and Proliferation: The fungi grow and multiply once inside the body, forming colonies within the subcutaneous tissues. The fungal species commonly associated with eumycetoma include Madurella, Scedosporium, Pseudallescheria, and Fusarium.
• Inflammatory Response: The presence of the fungi triggers an immune response by the host. Inflammation occurs as the body’s immune system tries to eliminate the invading organisms. However, fungi have developed mechanisms to evade the immune response and establish chronic infections.
• Granule Formation: As the fungi grow and spread within the tissues, they form granules or grains aggregates. These granules are composed of fungal hyphae and other host tissue components, varying in color depending on the causative agent. The granules are a hallmark feature of eumycetoma and can be seen in the draining sinuses and abscesses.
• Tissue Damage and Bone Involvement: Over time, the progressive growth of the fungi and the associated inflammatory response lead to tissue damage, necrosis, and destruction. Eumycetoma can involve the skin and subcutaneous tissues and extend to deeper structures, including bones. Bone involvement can destroy bone and deform, leading to significant disabilities.

Etiology

The main etiological agents associated with eumycetoma:

• Madurella species: Madurella mycetomatis is one of the most common and well-known fungi causing eumycetoma. It is often found in tropical and subtropical regions, especially in certain parts of Africa and India.
• Scedosporium species: Scedosporium apiospermum and Scedosporium boydii (formerly known as Pseudallescheria boydii) are two species of Scedosporium that can cause eumycetoma. These fungi are ubiquitous in the environment and can be found in various settings worldwide.
• Fusarium species: Certain species of the Fusarium genus, such as Fusarium solani and Fusarium oxysporum, have been reported as causative agents of eumycetoma in different geographical regions.
• Pseudallescheria species: Apart from Scedosporium boydii, other species from the Pseudallescheria genus, such as Pseudallescheria ellipsoidea, have also been implicated in causing eumycetoma.

Genetics

Prognostic Factors

• Duration of Disease: The length of time since the onset of symptoms or diagnosis can be an important prognostic factor. Early detection and intervention are associated with better treatment outcomes than cases that have been present for an extended period.
• Delayed Diagnosis and Treatment: A delay in seeking medical attention or receiving appropriate treatment can worsen the prognosis. Early diagnosis and prompt initiation of therapy are crucial to prevent disease progression and complications.
• Extent of Tissue Involvement: The size and extent of the affected tissues, as well as the involvement of nearby structures such as bones, play a role in determining the severity of the disease and the potential for complications.
• Specific Causative Agent: The identity of the causative fungal species can influence the response to antifungal therapy and the overall prognosis. Some fungal species may resist standard antifungal medications, making treatment more challenging.
• Presence of Bone Involvement: Eumycetoma that involves bones can lead to bone destruction and deformities, which can have long-term implications for the patient’s functional outcomes and quality of life.
• Immune Status: The immune status of the affected individual can also impact the prognosis. Immunocompromised individuals may have a higher risk of severe and disseminated disease.
• Treatment Response: The response to antifungal therapy is a critical prognostic factor. Patients who show an early and favorable response to treatment are more likely to achieve remission and have better outcomes.

Clinical History

• Age Group: Eumycetoma can affect individuals of all ages. However, it is more commonly reported in adults, particularly those engaged in outdoor or agricultural activities in endemic regions.

Physical Examination

• Inspection: The healthcare provider will visually inspect the affected area for signs of swelling, nodules, or masses. Eumycetoma often presents painless, slowly progressive swelling with overlying skin changes. 
• Skin Changes: The skin over the affected area may show various changes, such as erythema (redness), hyperpigmentation (darkening), and induration (hardening). There may be multiple sinus tracts or fistulas that are discharging grains or purulent material. 
• Draining Sinuses: One of the hallmark features of eumycetoma is the presence of draining sinuses or fistulas. These channels connect the deeper infected tissues with the skin surface and discharge grains or granules. The healthcare provider will examine these sinuses for the presence of grains, which are the aggregates of the causative fungi. 
• Grains: The grains are tiny colored masses that are characteristic of eumycetoma. The healthcare provider will examine the draining discharge from the sinuses and fistulas to identify and examine these grains. 
• Tissue Palpation: The provider will gently palpate the affected area to assess the extent of involvement, any fluctuant or fluid-filled areas, and any involvement of deeper structures, such as bones. 
• Lymph Node Examination: In some cases, regional lymph nodes may be enlarged, indicating possible spread of the infection. The healthcare provider will check for the presence of lymphadenopathy in nearby areas. 
• Functional Assessment: Depending on the extent of involvement, the physical examination may include assessing functional limitations and deformities caused by the disease. Eumycetoma involving bones can lead to significant deformities and functional impairment. 

Age group

Associated comorbidity

• While eumycetoma can occur in otherwise healthy individuals, certain activities and occupations can increase the risk of acquiring the infection. Agricultural workers, farmers, and individuals who come into direct contact with soil and thorny plants are at higher risk. Eumycetoma is more prevalent in rural areas where people are frequently exposed to the causative fungi’s environmental sources.

Associated activity

Acuity of presentation

• The clinical presentation of eumycetoma is generally chronic and slowly progressive. The disease may start with a painless swelling or mass in the affected body part, most commonly the foot. The symptoms can be subtle initially, and patients may only seek medical attention once the disease has been present for a considerable time. As the infection progresses, the affected area may develop draining sinuses or fistulas that produce discharging grains. Over time, the infection can spread to deeper tissues, including bones, destroying bone and deformities.

Differential Diagnoses

The differential diagnosis of eumycetoma (fungal mycetoma) includes various conditions with chronic subcutaneous swellings, abscesses, or draining sinuses. Distinguishing eumycetoma from these other conditions can be challenging due to overlapping clinical features. Some of the key differential diagnoses to consider are:

• Bacterial Actinomycetoma: Actinomycetoma is a similar chronic subcutaneous infection, but certain Actinomyces and Nocardia genera bacteria cause it. Like eumycetoma, it presents as a painless swelling with draining sinuses and the production of granules. Differentiating between fungal and bacterial mycetoma may require histopathological examination and culture.
• Soft Tissue Abscess: A soft tissue abscess is a localized collection of pus within the tissues, typically caused by bacteria. It can present as a painful swelling with overlying redness and tenderness. Unlike eumycetoma, an abscess is more acute in onset and may not produce granules.
• Lipoma: A lipoma is a benign tumor composed of fat tissue. It presents as a soft, movable lump under the skin and is usually painless. Unlike eumycetoma, lipomas do not produce draining sinuses or granules.
• Foreign Body Granuloma: Granulomas can form in response to foreign bodies embedded in the skin, such as splinters or thorns. This can cause persistent swelling and may be mistaken for eumycetoma.
• Chronic Inflammatory Skin Conditions: Conditions like sarcoidosis, cutaneous tuberculosis, or leishmaniasis can cause chronic skin swellings and ulcerations that may resemble eumycetoma.
• Neoplastic Lesions: Rarely, certain tumors or malignancies can present as subcutaneous swellings that may mimic eumycetoma. Biopsy and histopathological examinations are often required to differentiate these conditions from eumycetoma.
• Botryomycosis: Botryomycosis is a rare chronic bacterial infection that can cause similar clinical features to eumycetoma, such as draining sinuses and granules. However, botryomycosis is caused by bacterial organisms, not fungi.
• Rhinosporidiosis: Rhinosporidiosis is a rare fungal infection caused by Rhinosporidium seeberi, and it can present as subcutaneous swellings with draining sinuses. It is more common in specific regions like India and Sri Lanka.

Laboratory Studies

Imaging Studies

Procedures

Histologic Findings

Staging

Treatment Paradigm

Medical Therapy:

• Antifungal Agents: Antifungal medications are the mainstay of medical treatment for eumycetoma. The specific antifungal drug and the duration of therapy depend on the identified causative fungus. Commonly used antifungal drugs for eumycetoma include itraconazole, ketoconazole, voriconazole, and posaconazole. Sometimes, a combination of antifungal agents may be necessary to respond better.
• Monitoring and Follow-up: During antifungal therapy, close monitoring of the patient’s response is essential. Periodic clinical examinations, imaging studies, and laboratory tests (e.g., cultures of draining sinuses) help assess the treatment’s efficacy and adjust the therapeutic regimen if needed.

Surgical Interventions:

• Debridement: Surgical debridement (removal of affected tissue) may be performed in cases of localized abscesses or soft tissue involvement. This helps to reduce the fungal burden and improve the response to antifungal therapy.
• Amputation: In advanced cases with extensive tissue involvement or severe bone destruction, amputation of the affected limb may be considered to prevent further infection spread and improve the patient’s overall quality of life.

Supportive Care:

• Wound Care: Proper wound care prevents secondary infections and facilitates healing. Regular cleaning, dressing changes, and appropriate wound care products are essential in managing eumycetoma.
• Pain Management: Eumycetoma can be associated with pain and discomfort, especially bone involvement. Pain management strategies, such as analgesics and pain-relieving medications, may be employed to improve the patient’s comfort.

by Stage

by Modality

Chemotherapy

Radiation Therapy

Surgical Interventions

Hormone Therapy

Immunotherapy

Hyperthermia

Photodynamic Therapy

Stem Cell Transplant

Targeted Therapy

Palliative Care

use-of-a-non-pharmacological-approach-for-treating-eumycetoma

Non-pharmacological approaches can be used as adjuncts to the medical and surgical treatment of eumycetoma (fungal mycetoma). While antifungal medications and surgical interventions are the mainstay of treatment, non-pharmacological approaches can support managing the condition and improving the patient’s quality of life. Some non-pharmacological approaches that can be considered include:

• Wound Care: Proper wound care is essential in managing eumycetoma to prevent secondary infections and promote healing. Regular cleaning, debridement of necrotic tissue, and appropriate dressing of the affected areas can help prevent complications and facilitate the resolution of the infection.
• Physical Therapy: Physical therapy may be beneficial in cases where eumycetoma has caused functional limitations or deformities. Through targeted exercises and techniques, physical therapists can help improve the range of motion, strength, and mobility in affected limbs.
• Occupational Therapy: Occupational therapy focuses on improving daily activities and functional abilities. For individuals with eumycetoma affecting the hands or feet, occupational therapy can help them adapt and learn new ways to perform essential tasks.
• Pain Management: Eumycetoma can be associated with pain, especially bone involvement. Non-pharmacological pain management techniques, such as heat therapy, cold therapy, or transcutaneous electrical nerve stimulation (TENS), may be used to alleviate discomfort.

Patient Education and Self-Care: Educating patients about their condition, treatment plan, and the importance of adherence to medical advice can enhance treatment outcomes. Encouraging self-care practices, such as keeping the affected area clean and dry, can improve wound healing.

Psychological Support: Dealing with a chronic condition like eumycetoma can be emotionally challenging. Psychological support, counseling, and support groups can help patients cope with the psychological impact of the disease and improve their overall well-being.

Prosthetics and Orthotics: In cases where eumycetoma has led to limb amputation or significant deformities, prosthetics or orthotics can aid in restoring function and mobility.

Role of Antifungal therapy for treating Eumycetoma

Antifungal therapy plays a central and critical role in treating eumycetoma (fungal mycetoma). It is the primary mode of medical treatment aimed at targeting the causative fungi responsible for the infection. Antifungal therapy eliminates or controls fungal growth, resolves infection, and prevents disease progression and complications. The treatment of eumycetoma (fungal mycetoma) is primarily based on azole antifungal therapy, guided by reported in-vitro susceptibility data. Azole antifungals, such as itraconazole and voriconazole, are the mainstay of medical treatment for eumycetoma caused by specific fungal species. These antifungal agents have demonstrated promising activity against certain causative fungi, such as Madurella mycetomatis.

Itraconazole:

Itraconazole, an antifungal medication, exerts its mechanism of action by inhibiting the synthesis of ergosterol, a vital component of the fungal cell membrane. This disruption of the cell membrane integrity leads to the loss of fungal cell viability, ultimately resulting in the death of the fungus. The mechanism of action of itraconazole involves several steps:

• Inhibition of Cytochrome P450 Enzymes: Itraconazole is a member of the azole class of antifungal drugs, which work by inhibiting the activity of cytochrome P450 enzymes, particularly cytochrome P450 14-alpha demethylase. This enzyme is essential for converting lanosterol to ergosterol, a process crucial for synthesizing fungal cell membranes.
• Disruption of Ergosterol Synthesis: By inhibiting the cytochrome P450 14-alpha demethylase, itraconazole interferes with ergosterol synthesis from lanosterol. Ergosterol is a critical component of the fungal cell membrane, providing structural integrity and fluidity to the membrane. The absence of ergosterol disrupts the fungal cell membrane, making it more porous and less stable.
• Accumulation of Toxic Sterols: Due to cytochrome P450 inhibition, the fungal cells accumulate toxic sterol intermediates, such as 14-alpha-methyl-3,6-diol and 3-keto sterols. These toxic sterols further disrupt the fungal cell membrane and interfere with essential cellular processes.
• Impaired Membrane Function: The loss of ergosterol and accumulation of toxic sterols lead to a dysfunctional fungal cell membrane, compromising its barrier function. This disruption disrupts essential cellular processes, causing cellular damage and ultimately leading to the death of the fungus.

Voriconazole:

Voriconazole is an antifungal medication used to treat eumycetoma (fungal mycetoma). It involves inhibiting a specific fungal enzyme called cytochrome P450 14-alpha demethylase. This enzyme is crucial for synthesizing ergosterol, a vital component of the fungal cell membrane. By inhibiting this enzyme, voriconazole disrupts the production of ergosterol, destabilizing the fungal cell membrane. This disruption compromises the fungal cell’s integrity, causing cellular damage and ultimately resulting in the death of the fungus. Voriconazole’s ability to interfere with ergosterol synthesis makes it effective against a wide range of fungal species, including those responsible for causing eumycetoma.

use-of-intervention-with-a-procedure-in-treating-eumycetoma

The main objective of these procedures is to remove infected tissue, reduce the fungal burden, and promote wound healing. Surgical interventions are typically considered in cases with extensive involvement, large masses, bone invasion, or when antifungal therapy alone cannot control the infection. Some common procedures used in the management of eumycetoma include:

• Surgical Debridement: Surgical debridement involves the removal of infected and necrotic tissue, including the characteristic grains formed by the fungus. Debridement helps to reduce the fungal burden, eliminate a source of ongoing infection, and enhance the effectiveness of antifungal therapy.
• Excision of Masses: In cases of large masses or swelling due to the accumulation of grains, surgical excision may be performed to remove the visible fungal tissue and relieve pressure on surrounding structures.
• Bone Debridement or Resection: Eumycetoma can sometimes invade bones, leading to osteomyelitis. In such cases, surgical debridement or partial bone resection may be necessary to remove infected bone tissue and prevent further bone destruction.
• Drainage of Abscesses: For cases with abscess formation, drainage of the abscesses may be performed to relieve pain, reduce the fungal load, and facilitate wound healing.
• Amputation: In severe cases with extensive involvement or when other treatment options have failed, amputation of the affected limb may be considered to remove the source of the infection and prevent its spread.

use-of-phases-in-managing-eumycetoma

The typical phases involved in managing eumycetoma:

• Diagnosis and Evaluation Phase: In this initial phase, the focus is establishing an accurate diagnosis of eumycetoma. Dermatologists identify the characteristic clinical features and obtain samples for laboratory analysis. Skin biopsies are performed to identify the causative fungal species through mycological examination. Imaging studies, such as X-rays, CT scans, or MRI, may be used to evaluate the extent of the infection and assess the involvement of underlying bones and soft tissues.
• Antifungal Therapy Phase: Antifungal therapy is initiated once the diagnosis is confirmed. Azole antifungals like itraconazole or voriconazole are commonly used as first-line treatments based on susceptibility testing and clinical response. Antifungal therapy is typically prolonged, often lasting for several months to years, depending on the extent and response to treatment.
• Surgical Intervention Phase: Surgical interventions may be necessary for extensive involvement, large masses, or bone invasion cases. Orthopedic, plastic, and general surgeons may perform procedures such as debridement, excision of masses, bone debridement, or drainage of abscesses. Surgical interventions aim to remove infected tissue, reduce the fungal burden, and promote wound healing.
• Wound Care and Rehabilitation Phase: After surgical interventions, specialists are crucial in postoperative wound management to prevent infections, promote healing, and minimize complications. Rehabilitation may be necessary for cases with functional impairment due to bone or soft tissue involvement.
• Follow-Up and Monitoring Phase: Regular follow-up and monitoring are essential to assess treatment response, identify relapses or complications, and adjust the treatment plan accordingly. This phase involves close collaboration between dermatologists, infectious disease specialists, surgeons, and wound care specialists.

Medication

Future Trends

Media Gallary

References

Mycetoma:pubmed.ncbi.nlm.nih

Molecular Detection and Identification: ncbi.nlm.nih

Global Burden of Human: ncbi.nlm.nih

Mycetoma:ncbi.nlm.nih